In general, our research uncovered that USP52 suppressed ferroptosis through the Hippo–YAP signaling and highlighted targeting USP52 as a potential therapeutic strategy to boost ferroptosis for enhancing cancer immunotherapy. The gene discussed is PAN2; the disease is cancer.